Towa Pharmaceutical Co., Ltd. TSE:4553
Towa Pharmaceutical : FY2025(2nd quarter) Supplementary Material of Financial Results(377K／26P)
Source: MarketScreener
2025
Notes to financial results disclosure material Notes
In this document, for the breakdown of the domestic segment,
Towa Pharmaceutical, J-Dolph Pharmaceutical, Daichi Kasei, Greencaps Pharmaceutical, and Kyushu Iyaku are referred to as "Towa Pharmaceutical, etc.," and Sunsho Pharmaceutical and Sun Freres Lab. are referred to as "Sunsho Pharmaceutical, etc."
On April 1, 2025, the Company carried out an absorption-type merger with Sunsho Pharmaceutical as the surviving company and KAMATA as the disappearing company.
Towa Pharma International Holdings, S.L., our overseas segment, is referred to as "Towa INT."
"Towa Pharmaceutical, etc." "Sunsho Pharmaceutical, etc." "Towa INT"
Towa Pharmaceutical
J-Dolph
Pharmaceutical Daichi Kasei
Greencaps Pharmaceutical
Kyushu Iyaku
Sunsho Pharmaceutical
Towa Pharma International Holdings
Sun Freres Lab.
Towa Pharma Europe
Breckenridge Pharmaceutical
Towa Pharmaceutical
2025 1
Table of contents
- Outline of financial results for 2026/3 2Q
- Reference materials
2025 2
Table of contents
- Outline of financial results for 2026/3 2Q
Reference materials
2025 3
Overall review of financial results for 2026/3 2Q
-
YoY change: Net sales increased, but operating profit decreased on a consolidated basis.
Net sales increased due to an increase in sales volume following an increase in production volume at Towa Pharmaceutical and growth in the domestic health food business at Sunsho Pharmaceutical.
Gross profit increased due to a drop in the cost of sales ratio due to the effect of new product launches at Towa INT, despite a rise in the cost of sales ratio at Sunsho Pharmaceutical.
Operating profit decreased due to a rise in the cost of sales ratio at Sunsho Pharmaceutical and an increase in SG&A expenses at Towa INT. Ordinary profit increased due to the posting of a 1.5 billion yen gain on valuation of derivatives.
- Progress rate for the full-year plan: Net sales: 46.6%, Operating profit: 38.7% on a consolidated basis
Net sales fell short of the 1H plan target due to the lower-than-expected sales volume of Towa Pharmaceutical and the poor performance in Towa INT for both the Europe and the U.S..
Gross profit fell short of the 1H plan target due to the lower-than-expected net sales of Towa Pharmaceutical and a higher-than-expected cost of
sales ratio of Sunsho Pharmaceutical and the European BtoB of Towa INT.
Operating profit fell short of the 1H plan target due to the poor performance of Sunsho Pharmaceutical and Towa INT, despite progressing as planned due to delays in spending on SG&A expenses of Towa Pharmaceutical.
Ordinary profit met the 1H plan target due to the posting of an unplanned 1.5 billion yen gain on valuation of derivatives.
26/3 2Q results | 25/3 2Q results | 26/3 1H plan | 26/3 full-year plan | ||||
(JPY billion) | YOY change (%) | (JPY billion) | (JPY billion) | Achievement rate (%) | (JPY billion) | Progress rate (%) | |
Net sales | 130.4 | + 5.7% | 123.4 | 134.5 | 97.0% | 280.0 | 46.6% |
Gross profit | 47.2 | + 5.1% | 44.9 | 50.1 | 94.2% | 104.0 | 45.4% |
Operating profit | 10.4 | - 0.7% | 10.5 | 12.0 | 87.0% | 27.0 | 38.7% |
Ordinary profit | 11.9 | + 15.9% | 10.3 | 11.1 | 107.9% | 25.3 | 47.3% |
Profit attributable to owners of parent | 8.2 | + 25.3% | 6.5 | 8.0 | 102.7% | 17.7 | 46.4% |
Exchange rate at end of period (TTM) USD 1 | 26/3 2Q | 25/3 4Q | 25/3 2Q | 24/3 4Q | |||
JPY 148.88 | JPY 149.52 | JPY 142.73 | JPY 151.41 | ||||
2025 4